(secondQuint)A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids.

 This is a phase 3, multicenter, randomized, double-blind,parallel-group,non-inferiority study to evaluate the efficacy and safety of TAK-385 administered orally in daily dosing 40 mg for 24 weeks, compared with leuprorelin injection (once/4 weeks, 1.

88 mg or 3.

75 mg subcutaneous [SC]/time) in premenopausal participants 20 years of age with symptomatic uterine fibroids.

 The primary objective of this study is to evaluate the efficacy of TAK-385 40 mg administered orally once daily for 12 weeks.

 Participants must be diagnosed to have uterine fibroids as confirmed by transvaginal ultrasound or other methods, and have symptoms of menorrhagia.

 The total number of participants to be randomized under double-blind conditions is 288 (144 participants each for the TAK-385 40 mg group or leuprorelin group).

.

 A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids@highlight

The purpose of this study is to evaluate the efficacy of TAK-385 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once/4 weeks, 1.

88 mg or 3.

75 mg SC/time) in participants with uterine fibroids.

